Jazz Pharmaceuticals has patented a method to enhance the safety and efficacy of GHB administration by concomitantly administering an MCT inhibitor like diclofenac, valproate, or ibuprofen. The patent aims to treat cataplexy in narcolepsy or excessive daytime sleepiness by adjusting GHB dosage with divalproex sodium to account for changes in PK and PD. GlobalData’s report on Jazz Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Jazz Pharmaceuticals Plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Jazz Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Jazz Pharmaceuticals's grant share as of May 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of cataplexy in narcolepsy with reduced ghb dosage

Source: United States Patent and Trademark Office (USPTO). Credit: Jazz Pharmaceuticals Plc

A recently granted patent (Publication Number: US11986446B2) discloses a method for treating patients suffering from cataplexy in narcolepsy or excessive daytime sleepiness. The method involves administering a reduced daily dosage of gamma-hydroxybutyrate (GHB), a prodrug, or a salt thereof, to the patient, while also concomitantly administering divalproex sodium. This reduced dosage compensates for pharmacokinetic (PK) and/or pharmacodynamic (PD) changes caused by the simultaneous administration of divalproex sodium. The patent specifies various dosage amounts and percentage reductions based on the patient's condition and response to treatment.

Furthermore, the method outlined in the patent involves monitoring the patient's response and adjusting the dosage of GHB, prodrug, or salt thereof accordingly. The dosage reduction ranges from about 15% to 30% compared to the standard dosage in the absence of divalproex sodium. The patent also includes specific measurements for assessing PK and PD changes, such as plasma concentration, Cmax, Cn, C24, Tmax, and Area Under the Curve (AUC). Additionally, the patient's condition and response are evaluated using Cognitive Drug Research (CDR) system tasks or a Karolinska Sleepiness Scale (K55). Overall, the patent provides a detailed method for effectively treating patients with cataplexy or excessive daytime sleepiness by adjusting the dosage of GHB or its prodrug in combination with divalproex sodium.

To know more about GlobalData’s detailed insights on Jazz Pharmaceuticals, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies